Pharma Enrico Allievi, President of the Italian OTC (Over The Counter) association, Assosalute, talks about the state of the OTC market in Italy, as well as the association’s role in creating value for its members and his outlook for the next five years. Enrico, to start off, could you explain Assosalute’s…
orphan drugs Aegerion’s representative in Argentina discusses her efforts to raise awareness of Homozygous Familial Hypercholesteremia (HoFH), the rare disease targeted by her company’s ultra-orphan drug, and the remaining challenges of diagnosing patients. What is the current state of affairs for HoFH patients in Argentina? So far, as lomitapide is not yet…
orphan drugs Gabriela Pittis discusses the Argentinian healthcare system’s ability to diagnose, treat, and regulate rare diseases, and the country’s progress in further developing what is already the region’s most comprehensive system in this regard. Is the Argentinian system able to reliably diagnose and treat rare diseases? “Rare diseases” is a…
Botanical drugs The Chairman and CSO of TCM Biotech offer perspectives on the potential of botanical drugs, and chart their biotech company’s trajectory in bringing these drugs to both the Chinese and US markets. Mr. Hsu, can you please introduce our readers to yourself and to TCM Biotech? Shining Hsu (SH): I…
Government Regulation As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate need for better legislation in this area for the benefit of patients, and the misconceptions of treating Canada as a…
Nordic Drugs Could you begin by giving a short introduction to Nordic Drugs and its current position within the structure of owner Nordic Group? Nordic Drugs started as a 100% owned subsidiary of Ferring in January 1995. Several years later, in 1998, we were divested out from Ferring. Today we are owned…
ireland Mr. Mazeman, can you please begin by offering a brief overview of your career to date? I am a French pharmacist by training, with expertise in pharmacology. I have worked for Servier for my entire career. I started in the industry as a medical representative for the company. I went…
India Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company? First of all, I am a scientist by background, and before founding Hetero I had been working at Dr. Reddy’s…
See our Cookie Privacy Policy Here